Clinical trial · Observational
Clinical Research of H3F3AK27M in Spinal Glioma and Its Impact on TMZ Chemoradiotherapy
Clinical Research of the Molecular Phenotype Distribution of H3F3AK27M in Spinal Glioma and Its Impact on TMZ Chemoradiotherapy
NCT03668522CI-TRIAL-00034825unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
H3F3AK27M may be a feature of primary spinal cord glioma and affect the outcome and prognosis of TMZ chemoradiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Spinal Tumor | Spinal Cord Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Genetic testing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- children
- description
- age\<=17
- interventionNames
- Other: Genetic testing
- label
- adult
- description
- age\>17
- interventionNames
- Other: Genetic testing
Primary outcomes (1)
- measure
- positive
- timeFrame
- through study completion, an average of 1 year
- description
- positive of H3F3AK27M
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Surgical treatment and pathological confirmation of spinal glioma in our department and is the first case without any treatment before operation. Exclusion Criteria: * The tumor is recurrent or has been treated before operation.
References
Publications (0)
Data not yet available
No reference posted for this study.